Werewolf Sells INDUCER and INDUKINE Platforms to EMD Serono for $28M Upfront
HOWL has more than doubled off its 52-week low of $0.27 on elevated volume (3.7× avg).
Summary
Werewolf Therapeutics sold its preclinical INDUCER and INDUKINE platforms to EMD Serono for $28M upfront plus $5M milestone, retaining rights to WTX-124 and WTX-330 clinical programs.
Key Events · M&A and Partnerships · HOWL
-
Asset Sale to EMD Serono
Sold INDUCER and INDUKINE platforms for $28.0M upfront plus $5.0M upon technology transfer completion.
-
Retained Clinical Programs
Company retains exclusive license to develop WTX-124 and WTX-330 clinical programs.
-
Cash Runway Extension
Proceeds significantly extend cash runway from $22M balance, addressing going concern risk.
-
Non-Competition Covenant
24-month non-competition on certain compounds targeting same tumor targets as transferred assets.
Analysis · HOWL · Life Sciences
Werewolf Therapeutics sold its preclinical INDUCER and INDUKINE platforms to EMD Serono for $28 million upfront plus $5 million upon technology transfer. The company retains rights to its WTX-124 and WTX-330 clinical programs through an exclusive license back. This deal provides critical cash to a company with only $22 million on hand and a going concern warning, while preserving its lead clinical assets. The non-competition covenant limits future platform exploitation but allows continued development of the retained programs.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21M. The 52-week trading range was $0.27 to $2.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.